Stephens Inc’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

Stephens Inc’s Portfolio NAVB Stock Details NAVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-750	Closed	-$14K	–	834
2016 Q3	$14K	Hold	750	–	–	﹤0.01%	765
2016 Q2	$8K	Buy	750 +50	+7%	+$982	﹤0.01%	760
2016 Q1	$13K	Hold	700	–	–	﹤0.01%	739
2015 Q4	$19K	Hold	700	–	–	﹤0.01%	733
2015 Q3	$32K	Buy	700 +25	+4%	+$943	﹤0.01%	730
2015 Q2	$22K	Hold	675	–	–	﹤0.01%	781
2015 Q1	$21K	Buy	675 +100	+17%	+$3.38K	﹤0.01%	796
2014 Q4	$22K	Hold	575	–	–	﹤0.01%	789
2014 Q3	$15K	Hold	575	–	–	﹤0.01%	795
2014 Q2	$17K	Hold	575	–	–	﹤0.01%	818
2014 Q1	$21K	Buy	575 +50	+10%	+$1.9K	﹤0.01%	774
2013 Q4	$22K	Buy	+525	New	+$20.5K	﹤0.01%	841

Other funds holding NAVB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

SFS

Sowell Financial Services North Little Rock, Arkansas $3.06B AUM 30.02% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

SIM

Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Stephens Inc's NAVB Position: Q4 2016 in Review

Stephens Inc sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q4 2016, closing a stake of 750 shares — an estimated $14K sold.

Stephens Inc first reported a position in NAVB in Q4 2013 and held it in 12 quarters. The position peaked at $32K in Q3 2015. 55 funds tracked by Wall St. Rank hold NAVB as of Q4 2016.

Stephens Inc reported no remaining Navidea Biopharmaceuticals Inc. position as of Q4 2016 after selling out during the quarter.
Stephens Inc sold 750 Navidea Biopharmaceuticals Inc. shares in Q4 2016, an estimated $14K.
Stephens Inc first reported a position in Navidea Biopharmaceuticals Inc. in Q4 2013 and held it in 12 quarters.
Stephens Inc's Navidea Biopharmaceuticals Inc. position peaked at $32K in Q3 2015.
55 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q4 2016.

Based on Stephens Inc's 13F filing for Q4 2016, filed 9 Feb 2017.